Jpmorgan Chase & CO Amicus Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FOLD
# of Institutions
313Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$282 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$275 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$239 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$235 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$227 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.75B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...